Acute leukemias in 2020: state of the art

Minerva Med. 2020 Oct;111(5):384-385. doi: 10.23736/S0026-4806.20.07049-4. Epub 2020 Sep 22.

Authors

Claudio Cerchione¹, Giovanni Martinelli²

Affiliations

¹ Unit of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy - [email protected].
² Unit of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy.

PMID: 32957743
DOI: 10.23736/S0026-4806.20.07049-4

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Acute Disease
Aminopyridines / therapeutic use
Antineoplastic Agents / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Congresses as Topic
Cytarabine / therapeutic use
Daunorubicin / therapeutic use
Gemtuzumab / therapeutic use
Glycine / analogs & derivatives
Humans
Leukemia / diagnosis
Leukemia / therapy*
Pyridines
Recombinant Fusion Proteins / therapeutic use
Staurosporine / analogs & derivatives
Staurosporine / therapeutic use
Triazines / therapeutic use
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors

Substances

Aminopyridines
Antineoplastic Agents
Antineoplastic Agents, Immunological
CPX-351
Pyridines
Recombinant Fusion Proteins
Triazines
Cytarabine
enasidenib
tagraxofusp
Gemtuzumab
FLT3 protein, human
fms-Like Tyrosine Kinase 3
Staurosporine
midostaurin
ivosidenib
Glycine
Daunorubicin